Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published ...
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...
Hosted on MSN17d
Regeneron to Report Q3 Earnings: What's in the Offing?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks ...
Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...
11d
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With the shares off about 30% since the surprising news of an ...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback